Novo Nordisk Pharmaceuticals (Philippines), Inc. and St. Luke’s Medical Center Global City have signed a Memorandum of Agreement (MOA) to enhance the diabetes management skills of the premiere hospital’s resident physicians and nurses.
Under the MOA, Novo Nordisk Pharmaceuticals (Philippines), Inc. will provide continuing medical education (CME) training and related materials on diabetes and insulin therapy to the resident doctors and nurses of St. Luke’s Medical Center Global City. These include the holding of workshops and lectures on diabetes management, insulin administration and patient education; development of training modules; and provision of demo kits and demo insulin pens.
“Through this training program, the endocrine section provides optimal care to diabetes patients by keeping our health care professionals updated on insulin management”, according to Dr. Michael Villa, Head, Section of Endocrinology, St. Luke’s Medical Center Global City.
“Our partnership with Novo Nordisk demonstrates our commitment to maintain the highest standards of patient care and diabetes management,” said Dr. Arturo S. De La Peña, Head, Medical Practice Group; and Medical Director, St. Luke’s Medical Center Global City.
“Novo Nordisk is honored to partner with one of the Philippines’ leading hospitals in achieving our shared goal of changing diabetes through better patient education and support, enhanced CME for healthcare professionals, and improved prevention, care and control of diabetes,” said Mr. Jeppe Theisen, General Manager, Novo Nordisk Pharmaceuticals (Philippines), Inc.[pq]This partnership is part of the increasing investment of Novo Nordisk in the Philippines and its people together with establishing new offices in Bonifacio Global City and launches of new insulin products.[/pq]
Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone replacement therapy. Novo Nordisk discovers and develops high-quality, innovative biological medicines and makes them accessible to patients throughout the world. It also aims to support the education of both the healthcare professionals and patients globally.
– J. Cecil Barrameda, Medical Observer